Cargando…
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study
BACKGROUND: DaxibotulinumtoxinA for Injection (DAXI) is botulinum toxin Type A formulated with a novel peptide excipient. Two pivotal, single-treatment, placebo-controlled trials demonstrated efficacy and safety for moderate or severe glabellar lines. OBJECTIVE: To further evaluate DAXI in a large,...
Autores principales: | Fabi, Sabrina G., Cohen, Joel L., Green, Lawrence J., Dhawan, Sunil, Kontis, Theda C., Baumann, Leslie, Gross, Todd M., Gallagher, Conor J., Brown, Jessica, Rubio, Roman G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752211/ https://www.ncbi.nlm.nih.gov/pubmed/32773446 http://dx.doi.org/10.1097/DSS.0000000000002531 |
Ejemplares similares
-
Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection
por: Glogau, Richard, et al.
Publicado: (2021) -
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
por: Gallagher, Conor J., et al.
Publicado: (2023) -
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
por: Humphrey, Shannon, et al.
Publicado: (2023) -
A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study
por: Green, Jeremy B., et al.
Publicado: (2021) -
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)
por: Carruthers, Jean D., et al.
Publicado: (2020)